Table 1.
Characteristics of human prostate cancer omics datasets investigated. Table summarising characteristics of publicly available cancer omics datasets and their patients. For each clinical attribute investigated, there was not necessarily data for each patient in the cohort.
| TCGA [43] | Glinsky [44] | Grasso [45] | Taylor [46] | Varambally [47] | Gerhauser [48] | Barbieri [49] | Ren [50] | Abida [51] | Dan [52] | Kumar [53] | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancertool name | TCGA | Glinsky | Grasso | Taylor | Varambally | N/A | N/A | N/A | N/A | N/A | N/A |
| cBioPortal name | TCGA Firehose Legacy | N/A | Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012) | Prostate Adenocarcinoma (MSKCC, Cancer Cell 2010) | N/A | Prostate Cancer (DKFZ, Cancer Cell 2018) | Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012) | Prostate Adenocarcinoma (SMMU, Eur Urol 2017) | Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019) | Metastatic Prostate Cancer SU2C/PCF Dream Team, Cell 2015) | Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016) |
| Number of patients (N) | 499 | 79 | 61 | 218 | 13 | 251 | 112 | 65 | 429 | 150 | 176 |
| Cancer type | Primary prostate adenocarcinoma | Recurrent (n = 37) and nonrecurrent (n = 42) disease | Heavily penetrated CRPC (n = 50), high grade localised PCa (n = 11) | Primary tumours (n = 81), metastatic disease (n = 37) | Primary tumours (n = 7), metastatic disease (n = 6) | Primary prostate adenocarcinoma | Prostate adenocarcinoma | Prostate adenocarcinoma | Metastatic CRPC | Metastatic CRPC | Primary and metastatic—mCRPC (n = 63) |
| Treatment (prior to specimen collection) | Naïve | Undergoing routine treatment | Prostatectomy, chemotherapy, hormone therapy, radiotherapy, palliative radiotherapy. Localised cancers were treatment naïve. | No information | No information | Treatment naïve (except for two patients receiving neoadjuvant hormone therapy) | Treatment-naïve | Treatment-naïve | Standard of care (including second generation antiandrogens)/enrolled in a clinical trial (e.g., targeted therapy) | Various—second generation antiandrogens, clinical trial, taxane chemotherapy | ADT followed by second-generation antiandrogens (following disease progression) and docetaxel chemotherapy |
| Method of sample collection | Radical prostatectomy | During therapeutic/diagnostic procedures | Rapid autopsy (CRPC) and radical prostatectomy (localised) | Radical prostatectomy | Radical prostatectomy and rapid autopsy | Radical prostatectomy | Radical prostatectomy | Radical prostatectomy | Radiographic-guided biopsy | Radiographic-guided biopsy | Rapid autopsy |
| Gleason grade | 5: - | 5: - | 5: - | 5: 2 (1%) | - | 5: - | 5: - | 5: - | 5: - | - | - |
| 6: 45 (9%) | 6: 15 (19%) | 6: - | 6: 101 (47%) | - | 6: 13 (11%) | 6: 4 (20%) | 6: 5 (8%) | 6: 15 (9%) | - | - | |
| 7: 244 (50%) | 7: 45 (57%) | 7: 2 (18%) | 7: 77 (36%) | - | 7: 86 (74%) | 7: 13 (65%) 7.5: 1 (5%) | 7: 37 (57%) | 7: 49 (29%) | - | - | |
| 8: 63 (13%) | 8: 10 (13%) | 8: 4 (36%) | 8: 19 (9%) | - | 8: 1 (1%) | 8: 2 (10%) | 8: 9 (14%) | 8: 23 (14%) | - | - | |
| 9: 135 (27%) | 9: 9 (11%) | 9: 5 (46%) | 9: 15 (7%) | - | 9: 15 (13%) | 9: - | 9: 12 (18%) | 9: 67 (40%) | - | - | |
| 10: 4 (1%) | 10: - | 10: - | 10: - | - | 10: 1 (1% | 10: - | 10: 2 (3%) | 10: 13 (8%) | - | - | |
| 11: - | 11: - | 11: - | 11: - | - | 11: - | 11: - | 11: - | 11: 1 (1%) | - | - | |
| Total patients (n) for whom a Gleason grade was available | 491 (100%) | 79 (100%) | 11 (100%) (High grade localised PCas only) |
214 (100%) | No data available | 116 (100%) | 20 (100%) | 65 (100%) | 168 (101%) | No data available | No data available |